
About Corcept
Corcept is a publicly listed company based in Menlo Park (United States) founded in 1998. The company has 500 employees. Its website corcept.com draws about 38 thousand monthly visits. Corcept offers products and services including Cortisol Modulation Pipeline. Its focus areas include Life Sciences, Metabolic Diseases and Drugs. Its legal entity is Corcept Therapeutics, Incorporated. Its competitors include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Developer of cortisol modulators for the treatment of various diseases. The company focuses on the discovery and development of drugs that modulate the effects of cortisol that target glucocorticoid receptor (GR) antagonists to treat a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases.
- Headquarters Menlo Park, United States
- Employees 500
- Stage Public
- SectorsHealthcare
- Website category Finance · Investing
- Website corcept.com
- Social LinkedIn X YouTube
- Legal Name Corcept Therapeutics Incorporated
- Annual Revenue$761.41 M (USD)12.79as on Dec 31, 2025
- Net Profit$98.17 M (USD)-29.74as on Dec 31, 2025
- EBITDA$46.69 M (USD)-66.24as on Dec 31, 2025
- InvestorsInvestor Growth Capital
& 4 more
- Employee Count500
Products & Services of Corcept
Corcept offers a comprehensive portfolio of products and services, including Cortisol Modulation Pipeline.
Develops treatments for diseases affected by cortisol through clinical trials.
Apps and channels of Corcept
its YouTube channel Corcept Therapeutics has 50 subscribers and 3 videos.
Videos from Corcept
The most watched videos on Corcept's YouTube channel, Corcept Therapeutics (50 subscribers). Click a video to play it here.
More on Corcept Therapeutics.
Funding Insights of Corcept
- Total Rounds 6
- First Round $3M
(Nov 2006)
- Investors Count 5
All 6 funding rounds of Corcept with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2011 | Post-IPO | – | – | ||
| Apr 2010 | $7.65M | Post-IPO | – | – | – |
| Oct 2009 | $18.01M | Post-IPO | – | – | – |
| Mar 2008 | $25.3M | Post-IPO | – | – | |
| Aug 2007 | $10.11M | Post-IPO | – | – | |
| Nov 2006 | $3M | Post-IPO | – | – | – |
5 investors in total: 5 institutional.
Investors in Corcept
Corcept has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Investor Growth Capital, Longitude Capital and Sutter Hill Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors | investorgrowthcapital.com | New York, United States | ||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
VC firm investing in the US | shv.com | Palo Alto, United States | ||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Funding is provided for breakout consumer brands by Paperboy Ventures. | paperboyventures.com |
Investor details for Corcept
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Corcept
179 people are tracked at Corcept (81 in leadership, 6 in board & advisors, 92 in team); the tracked headcount is 500.
| Name | Role | Group |
|---|---|---|
Joseph K Belanoff | CEO, President & Director | Leadership |
Charles Robb | Chief Business Officer | Leadership |
Niral Shah | Associate Director, Clinical Data Management | Leadership |
Jeff Dener | Director Of Chemical Development | Leadership |
Jana Cranmer Chow | Senior Director, Corporate Communications | Leadership |
Will K. | Director, Pipeline & Portfolio Market Planning | Leadership |
Kavitha Seenivasan | Associate Director, Clinical Data Management | Leadership |
Amy Flood | Chief Human Resources & Communications Officer | Leadership |
Amiel Balagtas | Vice President, Development Operations | Leadership |
Alan Arroyo | Vice President, Clinical Development Operations | Leadership |
Anupma Roy | Director Of Clinical Operations | Leadership |
Danielle Cascerceri | Senior Director, Franchise Strategy | Leadership |
Liz Ruskay | Associate Director, Learning & Development | Leadership |
Steven Ross | Vice President Human Resources | Leadership |
Alejandra Preciado | Associate Director, Financial Planning & Analysis | Leadership |
Lauren Wiser | Senior Director Product Development | Leadership |
Heather Zimmerman | Senior Director, Legal | Leadership |
Kanoti Kim | Vice President, Financial Planning And Analysis | Leadership |
Shameek Ghose | Vice President, Intellectual Property | Leadership |
Gavin Williams | Vice President, Market Planning & Operations | General Manager | Leadership |
159 more people are available in the full profile.
Complete people profiles for Corcept
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Corcept
Corcept is a publicly listed company on the NASDAQ with ticker symbol CORT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Apr 2004
- Listed onNASDAQ: CORT
- Listed entityCorcept Therapeutics Incorporated
- Exchange sectorHealth technology
- ISINUS2183521028
- Share price$117.80 (-2.8% on the day) · 2026-10-13
- Market capitalisation$12.73B
- Price to earnings281.3
- EPS (diluted, trailing year)$0.42
- Volume (last session)556,291
Financials of Corcept
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $761.4M | $98.2M | $46.7M |
| 2024 | $675.0M | $139.7M | $138.3M |
| 2023 | $482.4M | $105.5M | $108.3M |
| 2022 | $401.9M | $101.3M | $115.6M |
| 2021 | $366.0M | $112.5M | $127.5M |
Detailed financial statements for Corcept
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Corcept
4 dated milestones of Corcept across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Corcept is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.0M.
- Funding Latest funding round, Post-IPO,.
Competitors of Corcept
Corcept has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies |
Detailed competitors of Corcept
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Corcept
The website of Corcept (corcept.com) receives about 38.2K visits a month and ranks #779,816 among all websites worldwide, #7,452 in Investing.
- Monthly visits38.2K
▲ 13.3% vs previous month
- Unique visitors15.7K
per month
- Global rank#779,816
among all websites
- Category rank#7,452
Finance · Investing
- Bounce rate38%
- Pages per visit3.1
- Average visit3 min 56 sec
- DevicesDesktop 61% · Mobile 39%
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Corcept (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Corcept
Complete news archive for Corcept
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Corcept
Corcept was founded in 1998 and raised its 1st funding round 8 years after it was founded.
Corcept is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Corcept has 500 employees.
Annual revenue of Corcept is $761.41M as on Dec 31, 2025.
Developer of cortisol modulators for the treatment of various diseases. The company focuses on the discovery and development of drugs that modulate the effects of cortisol that target glucocorticoid receptor (GR) antagonists to treat a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases.
Corcept's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
Corcept offers Cortisol Modulation Pipeline.
Yes, Corcept is publicly traded on NASDAQ under the ticker symbol CORT.
Corcept has 5 investors. Key investors include Investor Growth Capital, Longitude Capital, Sutter Hill Ventures, Alta Partners, and Paperboy Ventures.
Corcept operates through Corcept Therapeutics, Incorporated.
